Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507329-40-00

Acronym

PCYC-1145-LT

Enrollment

125

Registered

2024-08-16

Start date

2017-09-28

Completion date

Unknown

Last updated

2025-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

1. Follicular Lymphoma 2. Chronic Lymphocytic Leukemia 3. Waldenstrom macroglobulinemia 4. Multiple Myeloma 5. Marginal Zone Lymphoma 6. Diffuse Large B-Cell Lymphoma 7. Urothelial Carcinoma 8. Breast Cancer 9. Acute Myeloid Leukemia 10. Graft vs Host Disease 11. Mantle Cell Lymphoma

Brief summary

Assessment of percentage of patients rolling over from each parent study

Detailed description

Number of participants with treatment emergent serious adverse events and adverse events of special interest as assessed by CTCAE v4.0.

Interventions

DRUGIbrutinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Assessment of percentage of patients rolling over from each parent study	—

Secondary

Measure	Time frame
Number of participants with treatment emergent serious adverse events and adverse events of special interest as assessed by CTCAE v4.0.	—

Countries

Czechia, France, Hungary, Italy, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026